With 42% of Americans considered obese1, GLP-1 drugs have become one of the most buzzworthy trends among US consumers with awareness growing to over 80%2 in the last year and a predicted 70 million drug users by 20283.

While consumers are enjoying the results of the drug there are concerns and fears about long-term use and side effects4 driving interest in natural alternatives and companion products for those cycling on and off these medications.

In this webinar, learn how Solnul® can enhance your metabolic health via the microbiome. Dr. Jason Bush will guide you through the research and explain how Solnul® can be the cornerstone ingredient for brands targeting GLP-1-related and metabolic health markets.

In this webinar, Dr. Jason Bush will cover:

  • The Gut’s Central Role in Metabolic Health: How the gut microbiome influences metabolic health and FFA levels via improved bile acid metabolism.

  • Microbiome Modulators: How increasing levels of beneficial gut microbes like Akkermansia that are linked to GLP-1 can promote better metabolic outcomes.

  • Solnul® as The Prebiotic for Metabolic Health Formulations: How Solnul® meets consumer demand with substantiated claims for “prebiotic,” “well-tolerated,” and “regularity,” perfect for metabolic health and GLP-1 companion products.

Please enter your email to watch the webinar:

References

1. National Centre for Health Statistics, National Health and Nutrition Examination 2020
2. KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs
3. Goldman Sachs, February 2024
4. The New Consumer – Consumer Trends 2024: Mid-Year Report